Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $1.39 in the prior trading day, Coherus Biosciences Inc (NASDAQ: CHRS) closed at $1.32, down -5.04%. In other words, the price has decreased by -$5.04 from its previous closing price. On the day, 2.1 million shares were traded. CHRS stock price reached its highest trading level at $1.4278 during the session, while it also had its lowest trading level at $1.315.
Ratios:
Our goal is to gain a better understanding of CHRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.09 and its Current Ratio is at 1.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 152081168 and an Enterprise Value of 324266688. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.50. Its current Enterprise Value per Revenue stands at 1.065 whereas that against EBITDA is -2.773.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.82, which has changed by -0.39565217 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.97, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -0.99%, while the 200-Day Moving Average is calculated to be -11.09%.
Shares Statistics:
The stock has traded on average 4.95M shares per day over the past 3-months and 1742490 shares per day over the last 10 days, according to various share statistics. A total of 115.21M shares are outstanding, with a floating share count of 110.97M. Insiders hold about 4.01% of the company’s shares, while institutions hold 65.90% stake in the company. Shares short for CHRS as of 1735603200 were 30715772 with a Short Ratio of 6.21, compared to 1732838400 on 30717116. Therefore, it implies a Short% of Shares Outstanding of 30715772 and a Short% of Float of 31.11.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Coherus Biosciences Inc (CHRS).The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.3 and -$0.71 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is $0.01, with 4.0 analysts recommending between $0.21 and -$0.14.
Revenue Estimates
6 analysts predict $43.88M in revenue for the current quarter. It ranges from a high estimate of $58.9M to a low estimate of $36.42M. As of the current estimate, Coherus Biosciences Inc’s year-ago sales were $91.52MFor the next quarter, 6 analysts are estimating revenue of $60M. There is a high estimate of $60M for the next quarter, whereas the lowest estimate is $60M.
A total of 7 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $275M, while the lowest revenue estimate was $243.6M, resulting in an average revenue estimate of $255.58M. In the same quarter a year ago, actual revenue was $257.24MBased on 5 analysts’ estimates, the company’s revenue will be $279.18M in the next fiscal year. The high estimate is $312.88M and the low estimate is $240.27M.
